Recorded Presentations from the NCCN 2021 Virtual Congress: Biomarkers in Solid Tumors

Individualizing cancer treatment based upon biomarker testing is a rapidly evolving area in oncology. Clinicians are challenged to remain current on what the different tests offer, the types of genetic alterations that can be detected, the technologies that can be used, the limitations of the techniques, and the factors to consider in determining the appropriate tests for their patients with solid tumors.

The NCCN 2021 Virtual Congress: Biomarkers in Solid Tumors addressed the increasing use of biomarker testing in the management of patients with solid tumors, the factors affecting the selection of the appropriate tests, challenges of interpreting test results and communicating the results to patients, and new developments in biomarker testing. Case scenarios were employed to assist clinicians in applying biomarker testing in the management of metastatic non-small cell lung cancer, metastatic breast cancer, melanoma, ovarian cancer, and colorectal cancer.

Target Audience

This program is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with solid tumors.

Learning Objectives

Following this program, participants should be able to:

Apply the current standards of oncology care and the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) to appropriately integrate biomarker testing to optimize the care of patients with solid tumors.
Select the appropriate biomarker tests to evaluate and optimally manage patients with solid tumors.
Analyze and interpret the results of biomarker tests to select appropriate treatments for patients.
Communicate the results of biomarker tests with patients to inform their care.
Communicate with members of the interprofessional oncology care team about the use of biomarker testing in the management of patients with solid tumors.

Additional information

Supporters:

This activity is supported by educational grants from:

AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Eisai
Exact Sciences
Genentech, a member of the Roche Group
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Lilly
Novartis

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Merck & Co., Inc.

This activity is supported by an independent medical education grant from Illumina Corporate Foundation.

Course summary

Course opens:

12/20/2021

Course expires:

12/20/2022

Cost:

$0.00

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Congress Co-Chairs

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Kimberly H. Allison, MD
Devicor Medical Products, Inc.: Consulting Fee

Jennifer J.D. Morrissette, PhD
Bayer HealthCare: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee

Presenting Faculty

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Donald A. Baldwin, PhD
Terri L. Blase, MS, CGC
Jeffrey Gagan, MD, PhD

Dara L. Aisner, MD, PhD
Blueprint Medicines: Consulting Fee
Genentech, Inc.: Grant/Research Support
Loxo Oncology: Consulting Fee
sanofi-aventis U.S.: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Dana Farengo-Clark, MS, LCGC
AstraZeneca Pharmaceuticals LP: Product/Speakers Bureau

Susan M. Domchek, MD
AstraZeneca Pharmaceuticals LP: Honoraria

Jonathan E. Dowell, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee
Genentech, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee

Kelsey A. Klute, MD
Agios, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Daiichi-Sankyo Co.: Consulting Fee
FibroGen, Inc.: Grant/Research Support
Incyte Corporation: Grant/Research Support
Pfizer Inc.: Consulting Fee

Anthony J. Olszanski, MD, RPh
Bristol-Myers Squibb Company: Scientific Advisor
Eisai Inc.: Scientific Advisor
Merck & Co., Inc.: Scientific Advisor

Aparna R. Parikh, MD, MS
Bristol-Myers Squibb Company: Grant/Research Support
C2i Genomics: Equity Interest/Stock Options
Checkmate Pharmaceuticals: Consulting Fee
Daiichi-Sankyo Co.: Grant/Research Support
Eli Lilly and Company: Consulting Fee
Genentech, Inc.: Grant/Research Support
Inivata Ltd.: Consulting Fee
Mirati Therapeutics Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Consulting Fee
Plexxikon: Grant/Research Support
PMV Pharmaceuticals, Inc.: Grant/Research Support
PureTech Health: Grant/Research Support
Roche Pharmaceuticals: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support

Benjamin J. Swanson, MD, PhD
Cogen Bioscience, Inc.: Equity Interest/Stock Options; Scientific Advisor

Melinda L. Telli, MD
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Blueprint Medicines: Scientific Advisor
G1 Therapeutics: Consulting Fee
Guardant Health: Scientific Advisor
Genentech, Inc.: Grant/Research Support; Scientific Advisor
Immunomedics, Inc.: Scientific Advisor
Lilly Oncology: Scientific Advisor
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Natera Inc.: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
OncoSec Medical: Grant/Research Support; Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Scientific Advisor

David T. Ting, MD
Advanced Cell Diagnostics, Inc. (Bio-Techne): Grant/Research Support
Foundation Medicine, Inc.: Consulting Fee
Nanostring Technologies: Honoraria
PanTher Therapeutics: Equity Interest/Stock Options; Officer, Director or Any Other Fiduciary Role
Pfizer Inc.: Consulting Fee
PureTech Health: Grant/Research Support
Ribon Therapeutics: Grant/Research Support
ROME Therapeutics: Consulting Fee; Equity Interest/Stock Options; Intellectual Property Rights; Royalty Income; Scientific Advisor
TellBio, Inc.: Equity Interest/Stock Options

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This program has been approved for AMA PRA Category 1 Credit™ for physicians and will award contact hours for nurses, pharmacists, and other health care professionals. Complete accreditation information is provided before each individual educational activity.

Status

Price

Title

Locked

$0.00Included

Recorded Presentations from the NCCN 2021 Virtual Congress: Biomarkers in Solid Tumors